News | July 18, 2025
Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The company showcased three core programs developed through this platform
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Subscribe To Our Newsletter & Stay Updated
